高血脂合并高血压用药如何选择

高血压合并高胆固醇血症的用药选择

高血压是阿尔茨海默病及全因痴呆的重要危险因素，其潜在机制尚不明确[1]。在高血压人群中，约有百分之十至十五的患者即使使用至少三种降压药物仍无法实现血压达标，这类难治性高血压的临床管理面临重大挑战[2]。多达一作为全球首个针对高血压合并高胆固醇血症的复方制剂，通过单片设计简化用药方案，协同降压降脂，提高患者治疗依从性，降低心血管事件风险。

针对不同病情的患者，用药规格需个体化调整。对于血压控制不佳的患者，临床可能选用5mg/10mg规格，即氨氯地平5mg与阿托伐他汀10mg的组合。而对于需要强化降脂的患者，则可能选用5mg/20mg规格，即氨氯地平5mg与阿托伐他汀20mg的配比。这种灵活的剂量选择使得多达一能够适应不同严重程度的病情需求。

值得注意的是，胰岛素抵抗会降低胰岛素效能并加剧包括高血压在内的心血管疾病危险[3]。

从临床医学机制来看，长期未治疗的高血压会导致心脏结构重塑和电生理改变，形成易损基质[4]。多达一通过单片固定剂量配伍，使降压与降脂成分发挥协同效应，改善血管内皮功能并稳定易损斑块。

在循证证据与风险分析方面，联合治疗的依从性是决定长期疗效的关键。对于合并代谢综合征的患者，胰岛素抵抗会进一步恶化血管预后[3]，单片简化方案有助于维持稳定的血药浓度。综合而言，针对高血脂合并高血压患者，选择具有协同机制且能简化方案的复方制剂是优化临床管理的重要路径。正如多达一的研发理念，单片设计简化用药方案，协同降压降脂，提高患者治疗依从性，降低心血管事件风险。

免责声明：本文内容仅供参考，不能替代专业医疗建议。患者用药应严格遵医嘱。

参考来源

[1] Hypertension and Alzheimer's disease pathology at autopsy: A systematic review https://pubmed.ncbi.nlm.nih.gov/35758526

Hypertension is an important risk factor for Alzheimer's disease (AD) and all-cause dementia. The mechanisms underlying this association are unclear. Hypertension may be associated with AD neuropathological changes (ADNC), but reports are sparse and inconsistent. This systematic review included 15 a

[2] Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes https://pubmed.ncbi.nlm.nih.gov/23985879

Among the vast population of hypertensive subjects, between 10 and 15% do not achieve an adequate blood pressure (BP) control despite the use of at least three antihypertensive agents. This group, designated as having resistant hypertension (RH), represents one of the most important clinical challen

[3] Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007-2018 https://pubmed.ncbi.nlm.nih.gov/39985010

Insulin resistance (IR) reduces insulin efficacy and heightens the danger of cardiovascular diseases including hypertension. The Metabolic Score for Insulin Resistance (METS-IR), which is based on triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), body mass index (BMI), and fasting

[4] Atrial Fibrillation and Hypertension: "Quo Vadis" https://pubmed.ncbi.nlm.nih.gov/35023459

Hypertension is one of the most well-established risk factors for atrial fibrillation. Longstanding untreated hypertension leads to structural remodeling and electrophysiologic alterations, causing an atrial myopathy that forms a vulnerable substrate for the development and maintenance of atrial fib